The Chosun Ilbo on MSN

South Korea Sees 40% Jump in Mental Disorder Patients, Led by Depression

Last year, approximately 2.83 million patients in South Korea received treatment for mental disorders, marking an increase of nearly 40% (780,000 patients) compared to five years ago in 2019. This ...
The American Journal of Managed Care

FDA Approves Lumateperone as Add-On Therapy for Major Depressive Disorder

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

US FDA expands use of J&J's Caplyta as add-on depression drug

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday.